ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2026
Fibroelastic Remodelling of the Endocardium on the Right Side of the Heart: Endothelial-to-Mesenchymal Transition in Pulmonary Atresia With Intact Ventricular Septum.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesPatients with pulmonary atresia/critical pulmonary stenosis with intact ventricular septum (PA/cPS-IVS) show fibrous subendocardial tissue of unclear origin accompanied by right ventricular (RV) hypoplasia. While in hypoplastic left heart syndrome, it is known that flow-induced endothelial-to-mesenchymal transition (EndMT) of endocardial endothelial cells (EECs) is the source of this fibrous tissue, it remains unclear whether similar mechanisms exist in PA/cPS-IVS.
methodsWe analysed 13 PA/cPS-IVS patients who underwent staged ventricular rehabilitation surgery aimed at preserving RV function between March 2021 and July 2025 at Boston Children's Hospital. Resected tissue was examined for the degree of fibrosis and elastin and the presence of active EndMT by histology, immunohistochemistry, and flow cytometry. To mimic human disease conditions, isolated EECs were exposed to pathological flow and compared with physiological flow conditions.
resultsFlow disturbances across the pulmonary and/or tricuspid valves were present in all patients. Resected RV tissue revealed an active subendocardial fibroelastic remodelling process, infiltrating into the underlying myocardium. Patients showed RV diastolic dysfunction, as evidenced by elevated filling pressures, suggesting a pathophysiological role of fibroelastic remodelling of the endocardium. Mimicking the human disease, exposure of isolated EECs to pathological flow conditions induced loss of endothelial characteristics and transition towards a mesenchymal phenotype through EndMT.
conclusionsIn PA/cPS-IVS patients, restrictive RV physiology and diastolic dysfunction are likely driven by infiltrative fibroelastic remodelling caused by localized fibrogenic activation of EECs through EndMT in response to flow disturbances from valvular defects. Fibrogenic pathway activation may represent a promising therapeutic target in PA/cPS-IVS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.